Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc (formerly listed on Nasdaq under the symbol VRNA) generated a steady stream of news as a biopharmaceutical company focused on chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). Its news flow has covered the clinical development, regulatory progress and commercialization of its first-in-class COPD maintenance therapy Ohtuvayre (ensifentrine), as well as major corporate events culminating in its acquisition by Merck.
News articles about Verona Pharma include updates on the Phase 3 ENHANCE program for Ohtuvayre, where the drug met primary endpoints in ENHANCE-1 and ENHANCE-2 with statistically significant and clinically meaningful improvements in lung function. The company has also announced multiple scientific presentations at leading respiratory conferences such as the European Respiratory Society (ERS) International Congress and the American Thoracic Society (ATS) Conference, highlighting subgroup analyses on exacerbation rates, dyspnea, quality of life and outcomes in patients with comorbid conditions like cardiac disorders and type 2 diabetes.
Investors following VRNA-related news will also find corporate and financial updates, including quarterly financial results that detail Ohtuvayre net sales, prescription trends, prescriber adoption, and Verona’s funding and debt arrangements. Additional releases have described regulatory milestones, such as approval of Ohtuvayre in Macau through a development partner in Greater China and ongoing regulatory activities for potential marketing applications in other regions.
A key component of Verona Pharma’s news history is its strategic transaction with Merck. Press releases and SEC-related communications outline the July 2025 definitive agreement for Merck to acquire Verona Pharma, subsequent shareholder approval, court sanction of the scheme of arrangement, and Merck’s October 2025 announcement that the acquisition had closed and Verona Pharma had become a wholly owned subsidiary. Coverage of this process includes details of the cash consideration per ordinary share and per ADS and the resulting delisting of VRNA from the Nasdaq Global Market.
This news page serves as an archive of Verona Pharma’s historical announcements, from clinical and commercial milestones for Ohtuvayre to the corporate steps leading to its integration into Merck. Readers interested in the evolution of VRNA, the development of ensifentrine-based therapies, and the transaction that removed Verona Pharma from public markets can use this feed to review the company’s key public communications over time.
Ritedose, the largest CDMO in the US specializing in sterile Blow Fill Seal production, has partnered with Verona Pharma (Nasdaq: VRNA) to develop and manufacture Ohtuvayre (ensifentrine), a novel COPD treatment. The FDA approved Ohtuvayre on June 26 for maintenance treatment of COPD in adults, marking the first inhaled product with a new mechanism of action in over 20 years. Ohtuvayre, delivered via standard jet nebulizer, is a first-in-class PDE3 and PDE4 inhibitor that aims to redefine COPD treatment. With COPD affecting over 480 million people globally and 14 million in the US, this partnership between Ritedose and Verona Pharma brings a significant advancement to the respiratory market.
Verona Pharma (Nasdaq: VRNA) announces presentations of additional analyses from its Phase 3 ENHANCE studies on Ohtuvayre™ (ensifentrine) for COPD treatment at the ERS International Congress 2024. The presentations include one oral and three posters, highlighting Ohtuvayre's efficacy and safety in various COPD patient subgroups.
Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4, combines bronchodilator and anti-inflammatory effects. Key findings include improvements in lung function, reduced exacerbation rates, and enhanced quality of life across different patient populations. The analyses support Ohtuvayre's potential to benefit a broad range of COPD patients, marking the first novel inhaled mechanism for COPD maintenance treatment in over 20 years.
Verona Pharma (NASDAQ: VRNA) announced that Ohtuvayre (ensifentrine) is now available in the US for COPD maintenance treatment. Key highlights:
- Over 2,000 HCP visits conducted and 100+ unique HCPs have prescribed Ohtuvayre
- Submitted IND for ensifentrine-glycopyrrolate combination therapy
- Plans to initiate Phase 2 trial for non-cystic fibrosis bronchiectasis in Q3 2024
- Cash position of $404.6 million as of June 30, 2024
- Q2 2024 R&D expenses increased to $19.4 million (Q2 2023: -$2.5 million)
- Q2 2024 SG&A expenses rose to $49.0 million (Q2 2023: $12.4 million)
- Q2 2024 net loss of $70.8 million (Q2 2023: $8.8 million loss)
The company believes its current cash position will fund operations beyond 2026, including Ohtuvayre's US commercial launch.
Verona Pharma (Nasdaq: VRNA) has announced its participation in the 44th Annual Canaccord Growth Conference. The company's senior management will present a company overview on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.
Investors and interested parties can access a webcast of the event through the Events and Presentations link on the Investors page of Verona Pharma's website, www.veronapharma.com. This presentation provides an opportunity for the company to showcase its progress and future plans to a wider audience of potential investors and industry professionals.
For those seeking additional information, Verona Pharma has provided contact details for investor relations, US investor enquiries, and international/US media enquiries.
Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, with an audio replay accessible for 90 days.
Verona Pharma announced that the FDA has approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adults. Ohtuvayre is the first inhaled treatment in over 20 years offering both bronchodilation and non-steroidal anti-inflammatory effects. The drug is unique as a selective dual inhibitor of PDE3 and PDE4 enzymes and is administered via a standard jet nebulizer.
In clinical trials, Ohtuvayre showed significant benefits when used alone or with other treatments and was well-tolerated by patients with moderate to severe COPD. Verona Pharma plans to launch Ohtuvayre in Q3 2024 through specialized pharmacies.
Verona Pharma announces its financial results for the first quarter of 2024 and provides a corporate update. The PDUFA Target Action Date for Ensifentrine is set for June 26, 2024, with preparations underway for a potential US launch in the third quarter. The company's strong balance sheet, supported by a recent financing of up to $650 million, is geared towards commercialization and pipeline expansion. Key milestones include launch preparations, COPD disease awareness campaigns, presentations at conferences, and upcoming clinical trials. Financially, cash position remains strong, with R&D expenses and SG&A expenses detailed for the quarter.
Verona Pharma secured $650 million in strategic financing from Oaktree and OMERS to support the US commercial launch of ensifentrine and expand clinical activities. The non-dilutive funding extends the cash runway beyond 2026, providing financial flexibility for growth.
Verona Pharma plc will present additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for COPD treatment at ATS 2024. The investigational product, ensifentrine, has shown promising results in reducing exacerbations and improving lung function, with potential FDA approval as the first novel inhaled COPD treatment in over 20 years.
Summary not available.
FAQ
What is the current stock price of Verona Pharma (VRNA)?
What is the market cap of Verona Pharma (VRNA)?
